[1] |
Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer′s disease. Brain, 2008, 131(Pt 6): 1630-1645.
|
[2] |
Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci, 2007, 27(39): 10365-10371. doi: 10.1523/JNEUROSCI.0630-07.2007
|
[3] |
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer′s disease with Pittsburgh Compound-B. Ann Neurol, 2004, 55(3): 306-319. doi: 10.1002/ana.20009
|
[4] |
Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3): 257-262. doi: 10.1016/j.jalz.2011.03.004
|
[5] |
Raji CA, Becker JT, Tsopelas ND, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer′s disease with Pittsburgh Compound B. J Neurosci Methods, 2008, 172(2): 277-282.
|
[6] |
Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer′s disease. Brain, 2008, 131(Pt6): 1630-1645.
|
[7] |
Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol, 2009, 21(1): 117-128.
|
[8] |
Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging, 2011, 32 Suppl 1: S20-36.
|
[9] |
Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci, 2007, 27(23): 6174-6184. doi: 10.1523/JNEUROSCI.0730-07.2007
|
[10] |
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med, 2004, 256(3): 183-194.
|
[11] |
程怀东, 汪凯.遗忘型轻度认知损害的早期诊断途径:从分子、影像到行为神经病学.中国现代神经疾病杂志, 2010, 10(2): 155-159. doi: 10.3969/j.issn.1672-6731.2010.02.003
|
[12] |
Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 2007, 130(Pt11): 2837-2844.
|
[13] |
Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133(11): 3336-3348. doi: 10.1093/brain/awq277
|
[14] |
Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med, 2009, 360(22): 2302-2309. doi: 10.1056/NEJMoa0806142
|
[15] |
Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C-PiB and structural MRI provide complementary information in imaging of Alzheimer′s disease and amnestic mild cognitive impairment. Brain, 2008, 131(Pt3): 665-680.
|
[16] |
Jacobs B, Schall M, Prather M, et al. Regional dendritic and spine variation in human cerebral cortex: a quantitative golgi study. Cereb Cortex, 2001, 11(6): 558-571. doi: 10.1093/cercor/11.6.558
|
[17] |
Attems J, Thal DR, Jellinger KA. The relationship between subcortical tau pathology and Alzheimer's disease. Biochem Soc Trans, 2012, 40(4): 711-715.
|
[18] |
Tosun D, Schuff N, Mathis CA, et al. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain, 2011, 134(Pt4): 1077-1088.
|
[19] |
Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol, 2008, 65(11): 1509-1517. doi: 10.1001/archneur.65.11.1509
|
[20] |
Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol, 2010, 67(1): 122-131. doi: 10.1002/ana.21843
|
[21] |
Price JL, Davis PB, Morris JC, et al. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging, 1991, 12(4): 295-312. doi: 10.1016/0197-4580(91)90006-6
|
[22] |
Vlassenko AG, Benzinger TL, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta, 2012, 1822(3): 370-379. doi: 10.1016/j.bbadis.2011.11.005
|
[23] |
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3): 280-292. doi: 10.1016/j.jalz.2011.03.003
|
[24] |
Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry, 2010, 67(6): 584-587. doi: 10.1016/j.biopsych.2009.08.024
|
[25] |
Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol, 2010, 9(4): 363-372. doi: 10.1016/S1474-4422(10)70043-0
|
[26] |
Alexander D, Robert P. Imaging amyloid in the human brain: a promising tool for improved early diagnosis and treatment monitoring in Alzheimer′s Disease. Open Nucl Med J, 2010, 2: 53-57.
|